Boston- and Tel Aviv-based Converge Bio, which uses AI trained on molecular data to help pharma and biotech companies develop drugs, raised a $25M Series A — Artificial intelligence is moving quickly into drug discovery as pharmaceutical and biotech companies look for ways …
Posted from: this blog via Microsoft Power Automate.